Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Form 425 Mylan N.V. Filed by: Mylan N.V.

researchsnappy by researchsnappy
December 4, 2019
in Investment Research
0
Edison Issues Outlook on AFT Pharmaceuticals (AFT)
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

 

Umer Raffat – Evercore ISI Institutional Equities, Research Division – Senior MD & Senior
Analyst of Equity Research

But we shouldn’t expect — so there’s been conversations. This question is not on the pro forma
guidance, but there’s been a lot of questions on whether pro forma numbers are really $19 billion to $20 billion or is it closer to $18 billion top line. And there was a lot of comments where Mylan has sort of hinted at a lot of
things on the earnings call. But my question is, should we expect a meaningful update on that at JP Morgan? Or should we really wait for the earnings call?

 

 

Kenneth S. Parks – Mylan N.V. – CFO

I think we’ve got a way — I think we — as you can imagine, while the deal was announced July 29, there is a lot of
activity going on right now, including looking at the markets, bringing the commercial teams together to assess markets. I think we need to learn more to tell you how definitively we’ll tell you something at JP Morgan versus end of February
versus closer to the deal closing. So we’ll learn more to be able to give you more as soon as we reasonably can.

 

 

Umer Raffat – Evercore ISI Institutional
Equities, Research Division – Senior MD
 & Senior Analyst of Equity Research

Sounds
great. So next time is all China when we meet. Thank you, guys for being here.

Forward-Looking Statements

This transcript contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed
combination of Upjohn Inc. (“Newco”) and Mylan N.V. (“Mylan”), which will immediately follow the proposed separation of the Upjohn business (the “Upjohn Business”) from Pfizer Inc. (“Pfizer”) (the
“proposed transaction”), the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding
Pfizer’s, Mylan’s, the Upjohn Business’s or the combined company’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned
activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as “will”, “may”,
“could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”,
“pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties’ ability to meet expectations regarding
the timing, completion and accounting and tax treatments of the proposed transaction; changes in relevant tax and other laws; the parties’ ability to consummate the proposed transaction; the conditions to the completion of the proposed
transaction, including receipt of approval of Mylan’s shareholders, not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or
on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with accounting principles
generally accepted in the United States of America and related standards or on an adjusted basis; the integration of Mylan and Newco being more difficult, time consuming or costly than expected; Mylan’s, the Upjohn Business’s and the
combined company’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in
connection with the proposed transaction within the expected time frames or at all or to successfully integrate Mylan and Newco; customer loss and business disruption being greater than expected following the proposed transaction; the retention of
key employees being more difficult following the proposed transaction; any regulatory, legal or other impediments to Mylan’s, the Upjohn Business’s or the combined company’s ability to bring new products to market, including but not
limited to where Mylan, the Upjohn Business or the combined company uses its business judgment and decides to

Previous Post

Non-dairy sales cannot be ignored by dairy industry

Next Post

Hair Essential Trace Element and Mineral Content and ADHD in Two Age

Next Post
Hair Essential Trace Element and Mineral Content and ADHD in Two Age

Hair Essential Trace Element and Mineral Content and ADHD in Two Age

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

3 Best Market Research Certifications in High Demand

PRC needs full funding to do its job | My View

Plant-based Chicken Market 2021 by Global Key Players, Types, Applications, Countries, Industry Size and Forecast to 2030 – Energy Siren

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2023 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2023 researchsnappy.com